Abstract
L-3-[(18)F]-fluoro-α-methyl tyrosine ([(18)F]FAMT) is an amino acid positron emission tomography (PET) tracer with high specificity for malignant tumors through its selective transport via L-type amino acid transporter (LAT) 1. Although extensively studied for its diagnostic performance, a comprehensive review of its molecular and clinical characteristics remains lacking. A systematic literature review (1997-2025) was conducted using PubMed and Web of Science, with keywords including "L-3-[(18)F]-fluoro-α-methyl tyrosine", "[(18)F]FAMT", "amino acid PET", and "tumor imaging". The review covered aspects of synthesis, structural properties, pharmacokinetics, and clinical applications. Notably, while research on [(18)F]FAMT has declined significantly in recent years, [(18)F]FAMT PET demonstrates superior specificity to [(18)F]FDG PET in distinguishing malignancies from inflammatory lesions and offers distinct advantages in lung, esophageal, and oral cancers, though with slightly lower sensitivity. Its key features include tumor-specific uptake patterns, rapid blood clearance, and a significant correlation between its uptake levels and both LAT1 expression and tumor proliferation. In conclusion, [(18)F]FAMT is a promising PET tracer with notable advantages in tumor imaging, particularly due to its LAT1 selectivity and favorable pharmacokinetics. Despite challenges in production, these characteristics underscore its clinical value in cancers requiring precise imaging. Future research should focus on optimizing synthesis, expanding clinical validation, and exploring theranostic applications.